RIGL Q1 2020 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+341.7% YoY

Gross Profit

$56M99.7% margin

Operating Income

$21M37.7% margin

Net Income

$21M38.1% margin

EPS (Diluted)

$1.26

QoQ Revenue Growth

+262.1%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$143M

Total Liabilities

$65M

Stockholders' Equity

$78M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$13M	+341.7%
Gross Profit	$56M	$13M	+344.2%
Operating Income	$21M	-$18M	+214.4%
Net Income	$21M	-$18M	+220.7%

Revenue Segments

Contract Revenues From Collaborations

$43M39%

License

$40M36%

Gross Product

$15M14%

Product

$13M11%

Research And Development Services And Others

$3M3%

Discounts And Allowances

-$3M-2%